Market reaction to health care law: An event study
We investigate the effect of the U.S. Supreme Court’s decision to uphold President Obama’s health care reform (Patient Protection and Affordable Care Act), and other reform-related events, on the stocks of impacted firms. More specifically, we use an event study methodology to compute cumulative average abnormal returns (CAARs) for health insurance companies, hospitals, brand-name drug makers, and generic drug makers. Overall, we find that the law has a negative effect on health insurance companies, and on generic drug makers. On the other hand, it has a positive effect on hospitals and on brand-name drug makers.
- There are currently no refbacks.
is licensed under a Creative Commons Attribution 3.0 License
To make sure that you can receive messages from us, please add the 'macrothink.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Copyright © Macrothink Institute ISSN 2162-3082
'Macrothink Institute' is a trademark of Macrothink Institute, Inc.